The effect of xylazine and xylazine-etorphine- acepromazine combination on some clinical and haematological parameters in impala and eland.
D000075:Acepromazine / Q000008:administration & dosage / Q000494:pharmacology*; D000814:Aniline Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001188:Artiodactyla / Q000097:blood*; D001831:Body Temperature / Q000187:drug effects; D002118:Calcium / Q000097:blood; D003300:Copper / Q000097:blood; D004338:Drug Combinations; D004906:Erythrocyte Count; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D007103:Immobilization; D007958:Leukocyte Count; D008274:Magnesium / Q000097:blood; D009019:Morphinans / Q000008:administration & dosage / Q000494:pharmacology*; D000439:Pentanols / Q000008:administration & dosage / Q000494:pharmacology; D010758:Phosphorus / Q000097:blood; D012119:Respiration / Q000187:drug effects; D013843:Thiazines / Q000008:administration & dosage / Q000494:pharmacology*; D014992:Xylenes / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology
D000814:Aniline Compounds; D004338:Drug Combinations; D006454:Hemoglobins; D009019:Morphinans; D000439:Pentanols; D013843:Thiazines; D014992:Xylenes; D010758:Phosphorus; D000075:Acepromazine; D003300:Copper; D008274:Magnesium; D002118:Calcium